Advertisement

Journal of Neuro-Oncology

, Volume 72, Issue 2, pp 151–156 | Cite as

Apoptotic markers for primary brain tumor prognosis

  • A. E. Konstantinidou
  • P. Korkolopoulou
  • E. Patsouris
Clinical Study

Summary

Molecular studies of brain tumors have provided insights into pathogenesis, yet it is unclear how important these markers are in predicting clinical outcome and response to treatment. Quantitation of apoptosis by various techniques and the expression of several apoptotic markers have been studied in brain tumors, seeking to refine the information gained from established prognostic variables, which traditionally dictate therapeutic approaches. In the present review we discuss the role of the most extensively examined molecules involved in the apoptotic procedure, such as bcl-2, bax, fas/fasL, survivin and p53, as well as the incidence of baseline apoptosis in various brain tumors, in relation to prognosis. Summarizing current evidence, increased apoptosis and p53 genetic alterations have been advanced as adverse prognosticators in various types of central nervous system neoplasms, while bcl-2 expression appears to be deprived of any predictive value in primary brain tumors. The prognostic significance of the remaining apoptosis-related molecules remains controversial or too limited to draw any firm conclusions. The lack of unanimity of results mostly based on single-center retrospective studies underscores the necessity for large prospective randomized clinical trials, to elucidate the role of these molecular markers as determinants of clinical decision-making and as potential correlates of a pathobiologically tailored and individualized treatment strategy.

Keywords

apoptosis bax bcl-2 brain tumor fas p53 prognosis recurrence survival survivin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rudin, CM, Thompson, CB 1998Apoptosis and cancerVogelstein, BKinzler, KW eds. The Genetic Basis of Human Cancer.The McGraw-Hill companiesInc., New York193204Google Scholar
  2. 2.
    Harrington, EA, Fanidi, A, Evan, GI 1994Oncogenes and cell deathCurr Opin Genet Dev4120129CrossRefPubMedGoogle Scholar
  3. 3.
    Lowe, SW, Ruley, HE, Jacks, T, Housman, DE 1993P53 dependent apoptosis modulates the cytotoxicity of anticancer agentsCell74957967CrossRefPubMedGoogle Scholar
  4. 4.
    Hsu, B, Marin, MC, Brisbay, S, Mc Connell, K, McDonnell, TJ 1994Bcl-2 gene expression confers multidrug resistance to chemotherapeutic induced cell deathCancer Bull46125129Google Scholar
  5. 5.
    Dole, M, Nunez, G, Merchant, AK, Maybaum, J, Rode, CK, Bloch, CA, Castle, VP 1994Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastomaCancer Res5432533259PubMedGoogle Scholar
  6. 6.
    Grasl-Kraupp, B, Ryttkay-Nedecky, B, Koudelka, M, Bukowska, K, Bursch, W, Schulte-Hermann, R 1995In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis and autolytic cell death: a cautionary noteHepatology2114651468CrossRefPubMedGoogle Scholar
  7. 7.
    Frankfurt, OS, Robb, JA, Sugarbaker, EV, Villa, L 1996Monoclonal antibody to single-stranded DNA is a specific and cellular marker of apoptosisExp Cell Res226387397CrossRefPubMedGoogle Scholar
  8. 8.
    Frankfurt, OS, Robb, JA, Sugarbaker, EV, Villa, L 1997Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA. Relation to bcl-2 expression, hormone receptors and lymph node metastasesClin Cancer Res3465471PubMedGoogle Scholar
  9. 9.
    Korkolopoulou, P, Konstantinidou, A-E, Christodoulou, P, Patsouris, E, Thomas-Tsagli, E, Kapralos, P, Davaris, P 2000Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA. Relation to cell cycle regulators and survivalUrology56516520CrossRefPubMedGoogle Scholar
  10. 10.
    Korkolopoulou, P, Konstantinidou, AE, Patsouris, E, Christodoulou, P, Thomas-Tsagli, E, Davaris, P 2001Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNAJ Pathol193377382CrossRefPubMedGoogle Scholar
  11. 11.
    Konstantinidou, AE, Korkolopoulou, P, Patsouris, E, Mahera, H, Hranioti, S, Kotsiakis, X, Davaris, P 2001Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomasJ Neuro-oncol5519CrossRefGoogle Scholar
  12. 12.
    Earnshaw, WC 1995Nuclear changes in apoptosisCurr Opin Cell Biol7337343CrossRefPubMedGoogle Scholar
  13. 13.
    Korshunov, A, Golanov, A, Timirgaz, V 2000Immunohistochemical markers for intracranial ependymoma recurrence: an analysis of 88 casesJ Neurol Sci1777282CrossRefPubMedGoogle Scholar
  14. 14.
    Patsouris, E, Davaki, P, Kapranos, N, Davaris, P, Papageorgiou, K 1996A study of apoptosis in brain tumors by in situ end-labeling methodClin Neuropathol15337341PubMedGoogle Scholar
  15. 15.
    Kordek, R, Hironishi, M, Liberski, PP, Yanagihara, R, Gajdusek, DC 1996Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaksActa Neuropathol (Berl)91112116CrossRefGoogle Scholar
  16. 16.
    Heesters, MA, Koudstaal, J, Go, KJ, Molenaar, WM 1999Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical valueJ Neuro-oncol44255266CrossRefGoogle Scholar
  17. 17.
    Hara, A, Saegusa, M, Mikami, T, Okayasu, I 2001Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics and survivalJ Clin Pathol54860865PubMedGoogle Scholar
  18. 18.
    Bell, DA, Morrison, B 1991The spontaneous apoptotic cell death of normal human lymphocytes in vitro. The release of, and immunoproliferative response to, nucleosomes in vitroClin Immunol Immunopathol601326CrossRefPubMedGoogle Scholar
  19. 19.
    Uesugi, S, Yamashita, K, Nakashima, K, Ito, H 1998Apoptotic cell death induced by local brain hyperthermia in rat glioma modelActa Neuropathol96351356CrossRefPubMedGoogle Scholar
  20. 20.
    Migheli, A, Cavalla, P, Marino, S, Schiffer, D 1994A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaksJ Neuropathol Exp Neurol53606616PubMedGoogle Scholar
  21. 21.
    Iwaki, T, Miyazono, M, Hitotsumatsu, T, Tateishi, J 1994An immunohistochemical study of tissue transglutaminase in gliomas with reference to their cell-dying processesAm J Pathol145776781PubMedGoogle Scholar
  22. 22.
    Deininger, MH, Weller, M, Streffer, J, Meyermann, R 1999Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendrogliomasCancer8618321839CrossRefPubMedGoogle Scholar
  23. 23.
    Abramovich, CM, Prayson, RA 2000Apoptotic activity and bcl-2 immunoreactivity in meningiomas.Association with grade and outcomeAm J Clin Pathol1148492CrossRefPubMedGoogle Scholar
  24. 24.
    Naresch, KN, Lakshminarayanan, K, Pai, SA, Borges, AM 2001Apoptosis index is a predictor of metastatic phenotype in patients with early stage squamous carcinoma of the tongue: a hypothesis to support this paradoxical associationCancer91578584CrossRefPubMedGoogle Scholar
  25. 25.
    Harrington, EA, Fanidi, A, Evan, GI 1994Oncogenes and cell deathCurr Opin Genet Dev4120129CrossRefPubMedGoogle Scholar
  26. 26.
    Ehrmann, J,Jr, Rihakova, P, Hlobilkova, A, Kala, M, Kolar, Z 2000The expression of apoptosis-related proteins and the apoptotic rate in glial tumors of the brainNeoplasma47151155PubMedGoogle Scholar
  27. 27.
    Reed JC:, Bcl-2 1995prevention of apoptosis as a mechanism of drug resistanceHematol Oncol Clin North Am9451474PubMedGoogle Scholar
  28. 28.
    Ryan, JJ, Prochovnik, E, Gottlieb, CA, Apel, IJ, Merino, R, Nunez, G, Clarke, MF 1994C-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycleProc Natl Acad Sci USA9158785882PubMedGoogle Scholar
  29. 29.
    Fels, C, Schafer, C, Huppe, B, Bahn, H, Heidecke, V, Kramm, CM, Lautenschlager, C, Rainov, NG 2000Bcl-2 expression in higher-grade human glioma: a clinical and experimental studyJ Neurooncol48207216CrossRefPubMedGoogle Scholar
  30. 30.
    McDonald, FE, Ironside, JW, Gregor, A, Wyatt, B, Stewart, M, Rye, R, Adams, J, Potts, HW 2002The prognostic influence of bcl-2 in malignant gliomaBr J Cancer861899904CrossRefPubMedGoogle Scholar
  31. 31.
    Kraus, JA, Wenghoefer, M, Glesmann, N, Mohr, S, Beck, M, Schmidt, MC, Schroder, R, Berweiler, U, Roggendorf, W, Diete, S, Dietzmann, K, Heuser, K, Muller, B, Fimmers, R, Deimling, A, Schlegel, U 2002TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, BCL-2 and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiformeJ Neurooncol52263272CrossRefGoogle Scholar
  32. 32.
    Kajiwara, Y, Yamasaki, F, Hama, S, Yahara, K, Yoshioka, H, Sugiyama, K, Arita, K, Kurisu, K 2003Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosisCancer9710771083CrossRefPubMedGoogle Scholar
  33. 33.
    Frankel, B, Longo, SL, Ryken, TC 1999Co-expression of Fas and Fas ligand in human non-astrocytic glial tumorsActa Neuropathol (Berl)98363366CrossRefGoogle Scholar
  34. 34.
    Reis-Filho, JS, Faoro, LN, Carrilho, C, Bleggi-Torres, LF, Schmitt, FC 2000Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with world health organization grade 2 oligodendrogliomaCancer88862869CrossRefPubMedGoogle Scholar
  35. 35.
    Nakasu, S, Nakasu, Y, Nioka, H, Nakajima, M, Handa, J 1994Bcl-2 protein expression in tumors of the central nervous systemActa Neuropathol88520526PubMedGoogle Scholar
  36. 36.
    Mosnier, JF, Perret, AG, Brunon, J, Boucheron, S 1996Expression of the bcl-2 oncoprotein in meninigomasAm J Clin Pathol106652659PubMedGoogle Scholar
  37. 37.
    Konstantinidou, AE, Pavlopoulos, P, Patsouris, E, Kaklamanis, L, Davaris, P 1998Expression of apoptotic and proliferation markers in meningiomasJ Pathol186325330CrossRefPubMedGoogle Scholar
  38. 38.
    Schiffer, D, Cavalla, P, Migheli, A, Giordana, MT, Chiado-Piat, L 1996Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical studyJ Neurooncol27101109CrossRefPubMedGoogle Scholar
  39. 39.
    Hayashi, Y, Iwato, M, Arakawa, Y, Fujisawa, H, Thoma, Y, Hasegawa, M, Tachibana, O, Yamashita, J 2001Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell typeJ Neurooncol555158CrossRefPubMedGoogle Scholar
  40. 40.
    Korkolopoulou, P, Lazaris, AC, Konstantinidou, AE, Kavantzas, N, Patsouris, E, Christodoulou, P, Thomas-Tsagli, E, Davaris, P 2002Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survivalEur Urol40110Google Scholar
  41. 41.
    Ikeguchi, M, Maeta, M, Kaibara, N 2001Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancerInt J Mol Med7413417PubMedGoogle Scholar
  42. 42.
    Bargou, RC, Daniel, PT, Mapara, MY, Bommert, K, Wagener, C, Kallinich, B, Royer, HD, Dorken,  1995Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosisInt J Cancer60854859PubMedGoogle Scholar
  43. 43.
    Strik, H, Deininger, M, Streffer, J, Grote, E, Wickboldt, J, Dichgans, J, Weller, M, Meyermann, R 1999bcl-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapyJ Neurol Neurosurg Psychiatry67763768PubMedGoogle Scholar
  44. 44.
    Mazurek, U, Bierzynska-Macyszyn, G, Gola, J, Orchel, J, Slowinski, J, Wilczok, T 2001BCL2 and BAX mRNA concentration profile in fibrillary astrocytomaFolia Histochem Cytobiol39179180Google Scholar
  45. 45.
    Itoh, N, Yonehara, S, Ishii, A, Yonehara, M, Mizushima, S, Sameshima, M, Hase, A, Seto, Y, Nagata, S 1991The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell66233243CrossRefPubMedGoogle Scholar
  46. 46.
    Jong, S, Timmer, T, Heijenbrok, FJ, Vries, EG 2001Death receptor ligands, in particular TRAIL, to overcome drug resistanceCancer Metastasis Rev205156CrossRefPubMedGoogle Scholar
  47. 47.
    Strand, S, Hofmann, WJ, Hug, H, Muller, M, Otto, G, Strand, D, Mariani, SM, Stremmel, W, Krammer, PH, Galle, PR 1996Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion?Nat Med213611366CrossRefPubMedGoogle Scholar
  48. 48.
    Cheng, J, Zhou, T, Liu, C, Shapiro, JP, Brauer, MJ, Kiefer, MC, Barr, PJ, Mountz, JD 1994Protection from Fas-mediated apoptosis by a soluble form of the Fas moleculeScience26317591762PubMedGoogle Scholar
  49. 49.
    Ambrosini, G, Adid, A, Altieri, D 1997A novel anti-apoptosis gene, survivin, expressed in cancer and lymphomaNat Med3917921CrossRefPubMedGoogle Scholar
  50. 50.
    Li, F, Ambrosini, G, ChuE Plescia, J, Tognin, S, Marchisio, PC, Altieri, DC 1998Control of apoptosis and mitotic spindle checkpoint by survivinNature396580584CrossRefPubMedGoogle Scholar
  51. 51.
    Giodini, A, Kallio, MJ, Wall, NR, Gorbsky, GJ, Tognin, S, Marchisio, PC, Symons, M, Altieri, DC 2002Regulation of microtubule stability and mitotic progression by survivinCancer Res6224622467PubMedGoogle Scholar
  52. 52.
    Altieri, DC 2001The molecular basis and potential role of survivin in cancer diagnosis and therapyTrends Mol Med7542547CrossRefPubMedGoogle Scholar
  53. 53.
    Sasaki, T, Lopes, MB, Hankins, GR, Helm, GA 2002Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous systemActa Neuropathol (Berl)104105109CrossRefGoogle Scholar
  54. 54.
    Altura, RA, Olshefski, RS, Jiang, Y, Boue, DR 2003Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour gradeBr J Cancer8917431749CrossRefPubMedGoogle Scholar
  55. 55.
    Chakravarti, A, Noll, E, Black, PM, Finkelstein, DF, Finkelstein, DM, Dyson, NJ, Loeffler, JS 2002Quantitatively determined survivin expression levels are of prognostic value in human gliomasJ Clin Oncol2010631068CrossRefPubMedGoogle Scholar
  56. 56.
    Clarke, A, Purdie, C, Harrison, D, Morris, RG, Bird, CC, Hooper, ML, Wyllie, AH 1993Thymocyte apoptosis induced by p53-dependent and independent pathwaysNature362849852CrossRefPubMedGoogle Scholar
  57. 57.
    Louis, DN 1994The p53 gene and protein in human brain tumorsJ Neuropathol Exp Neurol531121PubMedGoogle Scholar
  58. 58.
    Shiraishi, T, Tabuchi, K 2003Genetic alterations of human brain tumors as molecular prognostic factorsNeuropathology2395108CrossRefPubMedGoogle Scholar
  59. 59.
    Vecil, GG, Lang, FF 2003Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenovirusesJ Neurooncol65237246CrossRefPubMedGoogle Scholar
  60. 60.
    Deininger, MH, Grote, E, Wickboldt, J, Meyermann, R 2000Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and bcl-2 in glioblastoma multiforme relapses in vivoJ Neurooncol48121129CrossRefPubMedGoogle Scholar
  61. 61.
    Rasheed, BK, McLendon, RE, Herndon, JE, Friedman, HS, Friedman, AH, Bigner, DD, Bigner, SH 1994Alterations of the TP53 gene in human gliomasCancer Res5413241330PubMedGoogle Scholar
  62. 62.
    Leenstra, S, Oskam, NT, Bijleveld, EH, Bosch, DA, Troost, D, Hulsebos, TJ 1998Genetic sub-types of human malignant astrocytoma correlate with survivalInt J Cancer79159165CrossRefPubMedGoogle Scholar
  63. 63.
    Watanabe, K, Sato, K, Biernat, W, Tachibana, O, Ammon, K, Ogata, N, Yonekawa, Y, Kleihues, P, Ohgaki, H 1997Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsiesClin Cancer Res3523530PubMedGoogle Scholar
  64. 64.
    Reifenberger, J, Ring, GU, GiesU Cobbers, L, Oberstrass, J, An, HX, Niederacher, D, Wechsler, W, Reifenberger, G 1996Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progressionJ Neuropathol Exp Neurol55822831PubMedGoogle Scholar
  65. 65.
    Xia, CL, Du, ZW, Liu, ZY, Huang, Q, Chan, WY 2003A2B5 lineages of human astrocytic tumors and their recurrenceInt J Oncol23353361PubMedGoogle Scholar
  66. 66.
    Pollack, IF, Finkelstein, SD, BurnhamJ Holmes, EJ, Hamilton, RL, Yates, AJ, Finlay, JL, Sposto, R 2001Children’s Cancer Group: Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohortCancer Res6174047407PubMedGoogle Scholar
  67. 67.
    Pollack, IF, Hamilton, RL, Finkelstein, SD,  et al. 1997The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhoodCancer Res57304309PubMedGoogle Scholar
  68. 68.
    Kros, JM, Godschalk, JJ, Krishnadath, KK, Van Eden, CG 1993Expression of p53 in oligodendrogliomasJ Pathol171285290CrossRefPubMedGoogle Scholar
  69. 69.
    Matsuno, A, Sasaki, T, Nagashima, T, Matsuura, R, Tanaka, H, Hirakawa, M, Murakami, M, Kirino, T 1997Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomasHum Pathol28714719CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • A. E. Konstantinidou
    • 1
  • P. Korkolopoulou
    • 1
  • E. Patsouris
    • 1
  1. 1.Department of Pathology, Faculty of MedicineNational Capodistrian University of AthensHalandriGreece

Personalised recommendations